Microfluidics expands the M-110P bench-top Microfluidizer® processor line with three new products

Pigment & Resin Technology

ISSN: 0369-9420

Article publication date: 9 January 2009

80

Citation

(2009), "Microfluidics expands the M-110P bench-top Microfluidizer® processor line with three new products", Pigment & Resin Technology, Vol. 38 No. 1. https://doi.org/10.1108/prt.2009.12938aad.011

Publisher

:

Emerald Group Publishing Limited

Copyright © 2009, Emerald Group Publishing Limited


Microfluidics expands the M-110P bench-top Microfluidizer® processor line with three new products

Microfluidics expands the M-110P bench-top Microfluidizer® processor line with three new products

Article Type: New products From: Pigment & Resin Technology, Volume 38, Issue 1

Microfluidics has expanded its range of product offerings by adding three new Microfluidizer® bench-top processors to its M-110P family. The new M-110P-20, M-110P-20S and M-110PS deliver all the features and benefits of the ground-breaking M-110P bench-top lab machine, while adding new capabilities and benefits to address the unique needs of the chemical industry.

M-110P family processors are used to create stable emulsions and the dispersion of incompatible chemicals or ingredients. As droplet size decreases and particles are more uniformly dispersed, the effectiveness of product performance increases. Additionally, these high shear fluid processors can also be used to achieve high color strength and gloss, and to reduce the amount of volatile organic compounds by increasing water content. Narrow size distribution, achieved by using these machines, prohibits the clogging of tiny inkjet nozzles. The M-110P processors also work to ensure high formulation stability and longer shelf life.

Like the original model, the new additions to the M-110P family require no compressed air or cooling water for hydraulics; the units also operate reliably, quietly and efficiently, and require only a standard 20 amp single phase electrical outlet. A CE compatible version of all three models is also being introduced.

The M-110P-20 is a new mid-pressured version of the higher-pressured M-110P model. It operates at a lower pressure and lower cost, is able to deliver nanoemulsions, nanosuspensions, nanoencapsulations and nanodispersions at 20,000 psi or lower, and works with a 50 ml minimum sample size. The M-110P-20 harnesses the company’s highly successful and time-tested ceramic interaction chamber to easily enable the production of nanoemulsions, nanosuspensions, nanoencapsulations and nanodispersions with the fewest number of passes.

The M-110PS and M-110P-20S Microfluidizer processors are designed to work with smaller minimum sample sizes of 25 ml. The M-110PS utilizes Microfluidics’ diamond interaction chamber technology, while the M-110P-20S utilizes Microfluidics’ ceramic interaction chamber technology, and both machines have a ceramic (Zirconia) plunger. All three new models include a glass reservoir for fast and accurate visual identification.

All products in the M-110P family allow flow rates starting at 110 ml/min (95 ml/min for CE versions) depending on process pressure, which is a higher flow rate than any comparable, competitive product. All results from this family of machines are guaranteed to be scaleable to pilot and/or production volumes.

About Microfluidics

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Related articles